CD8A and neoplasm: Experiments in mouse models of ESCA revealed that hindering the recruitment of TAMs through blockade of the CCL2–CCR2 axis considerably enhances the antitumor efficacy of CD8+ T cells in the TME, resulting in a significant reduction in tumor incidence.